May 15, 2024Verismo’s Synkir-310 receives FDA clearance for phase I trial in NHLVerismo Therapeutics Inc. has received IND clearance from the FDA to conduct a phase I trial with Synkir-310 for non-Hodgkin lymphoma (NHL).
May 13, 2024Ajax Therapeutics’ type II JAK2 inhibitor cleared to enter clinic for myelofibrosisAjax Therapeutics Inc. has received clearance for its IND application from the FDA to initiate a phase I study of AJ1‑11095, a first-in-class type II JAK2 inhibitor, for the treatment of patients with myelofibrosis.
May 8, 2024FDA clears IND for Biotheryx’s CDK4/6 degrader for breast cancerBiotheryx Inc. has gained FDA clearance for its IND application for BTX-9341, a novel cyclin-dependent kinase 4/6 (CDK4/6) bifunctional degrader.